Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production

Diabetes

Volumn 46, Issue 4, 1997, Pages 659-664

  Song, Jianben ^a   Walsh, Mary F ^a   Igwe, Robert ^a   Ram, Jeffrey L ^a   Barazi, Mohamad ^a   Dominguez, Ligia J ^a   Sowers, James R ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TROGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0030989050     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.4.659     Document Type: Article

References (53)

1. The National High Blood Pressure Education Program Working Group (Chair, James R. Sowers): National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes. Hypertension 23:145-158, 1994
2. Sowers JR, Epstein M: Diabetes mellitus and hypertension. I. An update. Hypertension 26:869-879, 1995
3. Warram JH, Martin BC, Krolewsld AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915, 1990
4. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329:1988-1992, 1993
5. Anderson EA, Mark AL: The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 21:136-141, 1993
6. Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension 21:129-135, 1993
7. Sowers JR, Sowers PS, Peuler JD: Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab and Clin Med 123:647-652, 1994
8. Zeroel MB, Reddy S, Sowers JR: Insulin attenuation of vasoconstrictor responses to phenylephrine in Zucker lean and obese rats. Am J Hypertens 4:537-539, 1991
9. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
10. Kahn A, Seidel CL, Allen JC, O'Neil RG, Shelat H, Song T: Insulin reduces contraction and intracellular calcium concentration in vascular smooth muscle. Hypertension 22:735-742, 1993
11. Ram JL, Fares MA, Standley PR, Therrell LL, Thyagaranjan RV, Sowers JR: Insulin inhibits vasopressin elicited contraction of vascular smooth muscle cells. J Vasc Med Biol 4:250-255, 1993
12. Standley PR, Ram JL, Sowers JR: Insulin attenuation of vascular smooth muscle calcium responses in Zucker lean and obese rats. Endocrinology 133:1693-1699, 1993
13. Chan JC, Tomlinson B Critchley JA, Cockram CS, Waiden RJ: Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16:1035-1038, 1993
14. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD: Effects of pioglitazone on L-type calcium channels in vascular smooth muscle. Hypertension 24:170-175, 1994
15. Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR: Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 137:113-121, 1996
16. Landin K, Tengborn L, Smith U: Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Int Med 229:181-187, 1991
17. Kotchen TA, Zhang HY, Reddy S, Hoffman RG: Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270:R660-R666, 1996
18. Kotchen TA: Attenuation of hypertension by insulin-sensitizing agents. Hypertension 28:219-223, 1996
19. Pershadsingh HA, Szollosi J Benson S, Hyun WC, Feuerstein BG, Kurtz TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21:1020-1023, 1993
20. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
21. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with Troglitazone. N Engl J Med 331:1188-1193, 1994
22. Kemnitz JW, Elson DF, Roecher EB, Baum ST, Bergman RN, Meglasson M: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 43:204-211, 1994
23. Ogihara, T, Rakugi H, Ikegami H, Mikaml H, Masuo K: Enhancement of insulin sensitivity by Troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertension 8:316-320, 1995
24. Fujita T, Sugiyama Y, Taketomi S, Sonda I, Kawamatsu I, Iwatsuka, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by ciglitazone, a new antidiabetic agent. Diabetes 32:804-810, 1983
25. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with oral antihyperglycemic agent pioglitazone. Endocrinol 129:1915-1925, 1991
26. Iwamoto Y, Kuzuya T, Matsuda A: Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
27. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
28. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
29. Hiragun A, Sato M, Mitsui H: Preadipocyte differrentiation in vitro: identification of a highly active adipogenic agent. J Cell Physiol 134:124-130, 1988
30. Spiegelman BM, Choy L, Hotamisligil GS, Graves RS, Tontonoz P: Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 2688:6823-6826, 1993
31. Sandouk T, Reda D, Hofmann C: The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleis acid transcript stability. Endocrinology 133:352-359, 1992
32. Sugriyama Y, Shimina Y, Ikeda H: Effect of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim-Frosch/Drug Res 40:436-440, 1990
33. Ikeda H, Taketomi S, Sugriyama Y, Shimura Y, Sohda T, Meguro K, Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim-Frosch/Drug Res 40:156-161, 1990
34. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin mediated skeletal muscle vasodilation is NO dependent: a novel action of insulin to increase NO release. J Clin Invest 94:1172-1179, 1994
35. Scherrer U, Randin D, Vollenweider L, Nicod P: NO release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515, 1994
36. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler NL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
37. Peuler JD, Johnson BA, Phare SM, Sowers JR: Sex specific effect of an insulin secretagogue in stroke-prone hypertensive rats. Hypertension 22:214-220, 1993
38. Zhang F, Ram JL, Standley PR, Sowers JR: 17β-estradiol attenuates voltage dependent current through Ca2* channels in a7r5 vascular smooth muscle cell line. Am J Physiol 266:C975-C980, 1994
39. Song J, Standley PR, Zhang F, Joshi D, Gappy S, Sowers JR, Ram JL: Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharm Exp Ther 277:1444-1453, 1996
40. Wu H-Y, Young YJ, Yue C-J, Kuang-Yuh C, Hsueh WA, Chan TM: Endothelial-dependent vascular effects of insulin and insulin-like growth factor 1 in the perfused rat mesenteric artery and aortic ring. Diabetes 43:1027-1032, 1994
41. Walsh MP, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR: Insulin-like growth factor 1 diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 137:1798-1803, 1996
42. Haylor J, Singh I, El-Nahas AM: NO synthesis inhibitor prevents vasodilation by insulin like growth factor-1. Kidney Int 39:333-335, 1991
43. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR: Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest 88:1230-1236, 1991
44. Bhagat B, Burke WJ, Dhalla NS: Insulin-induced enhancement of uptake of noradrenaline in atrial strips. Br J Pharmacol 74:325-332, 1981
45. Ram JL, Standley PR, Sowers JR: Calcium function in vascular smooth muscle and its relationship to hypertension. In Calcium Antagonists in Clinical Medicine. Epstein M, Ed. Philadelphia, Hanley and Belfus, 1995, p. 29-48
46. Dominguez LJ, Peuler JD, Sowers JR: Endocrine regulation of vascular smooth muscle intermediary metabolism. In Endocrinology of the Vasculature. Sowers JR, Ed. Clifton, NJ, Humana, 1996, p. 325-339
47. Plunkett WC, Overbeck HW: Arteriolar wall thickening in hypertensive rats unrelated to pressure or sympathoadrenergic influences. Circ Res 63:937-943, 1988
48. Zhang B, Szalkowski D, Diaz E, Hayes N, Smith R, Berger J: Potentiation of insulin stimulation of phosphatidylinosital 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem 269:25735-25741, 1994
49. Berger J, Biswas C, Hayes N, Veatre J, Wu M, Doebber TW: An antidiabetic thiazolidinedione potentates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology 137:1984-1990, 1996
50. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor a (PPARa). J Biol Chem 270:12953-12956,1995
51. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes 44:1087-1092, 1995
52. Geissler JF, Traxler P, Regenoss U, Murray BJ, Roesel JL, Meyer T, McGlynn E, Storni A, Lyden NB: Thiazolidinediones biochemical and biological activity of a novel class of tyrosine kinase inhibitors. J Biol Chem 265:22255-22261, 1990
53. Muniyappa R, Rangi JS, Zayas RM, Standley PR, Walsh MF, Sowers JR. Insulin-like growth factor-1 increases arterial smooth-muscle nitric oxide production. FASEB J 10:3804(A), 1996